Dermatology Life Quality Index as a Management Tool and Quality Indicator of Follow-up of Chronic Dermatoses

Background. Chronic inflammatory dermatoses—psoriasis, atopic dermatitis, and eczema—have a per­sistently high prevalence and a pronounced negative impact on patients’ quality of life. Current clinical guidelines issued by the Ministry of Health of the Russian Federation mandate the assessment of the Der­matology Life Quality Index (DLQI), yet its systematic integration into the follow-up care pathway is still structurally underdeveloped.

Objective. To substantiate an organizational model for using the Dermatology Life Quality Index (DLQI) as a management tool and quality indicator of the follow-up process by assessing DLQI levels in patients with moderate-to-severe chronic dermatoses.

Materials and methods. A single-center observational cross-sectional study was conducted at the Moscow Scientific and Practical Center of Derma­tovenereology and Cosmetology (2023-2026). Using unselected sampling, 105 patients aged 18-60 years with moderate-to-severe psoriasis (n=42), atopic dermatitis (n=38), or eczema (n=25) were enrolled. Disease severity was assessed with PASI, SCORAD, and EASI scores; quality of life was measured using the validated DLQI questionnaire. Statistical analysis was performed in IBM SPSS Statistics 26.0 using nonparametric methods, the chi-square test, and Spearman's rank correlation coefficient.

Results. The overall mean DLQI score was 14.8, indicating a very large effect on patient’s quality of life. The effect was slightly stronger in psoriasis (mean 15.6) than in atopic dermatitis (14.8) or eczema (13.4), with moderate between-group differences. No statistically significant difference in DLQI was found between sexes.

Conclusion. The mean DLQI score in the cohort was 14.8 (very large effect), highest in psoriasis (15.6) and lowest in eczema (13.4), with no signif­icant sex-related difference. The growing burden of psoriasis and atopic dermatitis in Moscow, especially in the post-pandemic period, together with significant quality-of-life impairment among patients with moderate-to-severe chronic dermatoses, supports a shift from episodic to systematic DLQI assessment and a pro­posed organizational model stratifying the follow-up care pathway by DLQI level, integrated with structured educational and psychosocial support (Patient Schools).

1. Hay R.J., Johns N.E., Williams H.C. et al. The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions. Journal of Investigative Dermatology. 2014;134(6):1527-1534. https://doi.org/10.1038/jid.2013.446

2. Karimkhani C., Dellavalle R.P., Coffeng L.E. et al. Global Skin Disease Morbidity and Mortality: An Update From the Global Burden of Disease Study 2013. JAMA Dermatology. 2017;153(5):406-412. https://doi.org/10.1001/jamadermatol.2016.5538

3. Parisi R., Iskandar I.Y.K., Kontopantelis E. et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. https://doi.org/10.1136/bmj.m1590

4. Damiani G., Bragazzi N.L., Karimkhani Aksut C. et al. The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study. Frontiers in Medicine. 2021;8:743180. https://doi.org/10.3389/fmed.2021.743180

5. Tian J., Zhang D., Yang Y. et al. Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study. British Journal of Dermatology. 2024;190(1):55-61. https://doi.org/10.1093/bjd/ljad339

6. Bylund S., von Kobyletzki L.B., Svalstedt M. et al. Prevalence and Incidence of Atopic Dermatitis: A Systematic Review. Acta Dermato-Venereologica. 2020;100(12):320–329. https://doi.org/10.2340/00015555-3510

7. Quaade A.S., Simonsen A.B., Halling A.S. et al. Prevalence, incidence, and severity of hand eczema in the general population – A systematic review and meta-analysis. Contact Dermatitis. 2021;84(6):361-374. https://doi.org/10.1111/cod.13804

8. Federal Statistical Observation Form No. 12 “Information on the number of diseases registered in patients living in the service area of a medical organization”: data from the medical information system of the Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology, 2015–2025. (In Russ.)

9. Kubanov A.A., Bogdanova E.V. Dermatovenereology of Russian Federation in 2020: Working Under a Pandemic. Vestnik Dermatologii i Venerologii. 2021;97(4): 8–32. https://doi.org/10.25208/vdv1261 (In Russ.)

10. Gudinova Zh.V., Okhlopkov V.A., Poleshchuk E.I. et al. Incidence of psoriasis depending on the region of the Russian Federation. Russian Journal of Skin and Venereal Diseases. 2018;21(2):85–89. https://doi.org/10.18821/1560-9588-2018-21-2-85-89 (In Russ.)

11. Kubanov A.A., Bogdanova E.V. Dermatovenereology in the Russian Federation: results of 2023. Vestnik Dermatologii i Venerologii. 2024;100(4): 9–24. https://doi.org/10.25208/vdv16795 (In Russ.)

12. Luna P.C., Chu C.Y., Fatani M. et al. Psychosocial Burden of Psoriasis: A Systematic Literature Review of Depression Among Patients with Psoriasis. Dermatology and Therapy. 2023;13:3043-3055. https://doi.org/10.1007/s13555-023-01060-5

13. Huang L., Feng Z., Xu C. et al. Stigma and psychological health in psoriasis patients based on the dual-factor model of mental health: the chain mediating roles of social appearance anxiety and alexithymia. Frontiers in Psychiatry. 2024;15:1499714. https://doi.org/10.3389/fpsyt.2024.1499714

14. Rønnstad A.T.M., Halling-Overgaard A.-S., Hamann C.R. et al. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis. Journal of the American Academy of Dermatology. 2018;79(3):448-456.e30. https://doi.org/10.1016/j.jaad.2018.03.017

15. LeBovidge J.S., Schneider L.C. Depression and anxiety in patients with atopic dermatitis: Recognizing and addressing mental health burden. Annals of Allergy, Asthma & Immunology. 2025;134(5):506-515. https://doi.org/10.1016/j.anai.2025.02.017

16. Finlay A.Y., Khan G.K. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clinical and Experimental Dermatology. 1994;19(3):210-216. https://doi.org/10.1111/j.1365-2230.1994.tb01167.x

17. Vyas J., Johns J.R., Ali F.M. et al. A Systematic Review of 207 Studies Describing Validation Aspects of the Dermatology Life Quality Index. Acta Dermato-Venereologica. 2024;104:adv41120. https://doi.org/10.2340/actadv.v104.41120

18. Bostoen J., Bracke S., De Keyser S. et al. An educational programme for patients with psoriasis and atopic dermatitis: a prospective randomized controlled trial. British Journal of Dermatology. 2012;167(5):1025- 1031. https://doi.org/10.1111/j.1365-2133.2012.11113.x

19. Sahin U., Reeve K., Tochtermann G. et al. HautTief Multidisciplinary Educational Program for Patients with Psoriasis or Atopic Dermatitis: A Randomized Controlled Study. Dermatology. 2022;238(6):1050-1059. https://doi.org/10.1159/000524225

20. Dressler C., Lambert J., Grine L. et al. Therapeutic patient education and self-management support for patients with psoriasis – a systematic review. Journal der Deutschen Dermatologischen Gesellschaft. 2019;17:685-695. https://doi.org/10.1111/ddg.13840

21. Hongbo Y., Thomas C.L., Harrison M.A. et al. Translating the Science of Quality of Life into Practice: What Do Dermatology Life Quality Index Scores Mean? Journal of Investigative Dermatology. 2005;125(4):659- 664. https://doi.org/10.1111/j.0022-202X.2005.23621.x

22. Basra M.K.A., Salek M.S., Camilleri L. et al. Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (DLQI): Further Data. Dermatology. 2015;230(1):27- 33. https://doi.org/10.1159/000365390

23. Kubanov A.A., Bakulev A.L., Fitileva T.V. et al. Disease Burden and Treatment Patterns of Psoriasis in Russia: A Real-World Patient and Dermatologist Survey. Dermatology and Therapy. 2018;8:581-592. https://doi.org/10.1007/s13555-018-0262-1

24. Arnīte A., Bondare-Ansberga V., Reinberga L. et al. Depression, Anxiety and Quality of Life in Patients with Atopic Dermatitis and Psoriasis. Medicina. 2026;62(1):164. https://doi.org/10.3390/medicina62010164

25. Raam L., Hartmane I., Valiukevičienė S. et al. Disease severity, treatment patterns, and quality of life in patients with moderate-to-severe psoriasis routinely managed with systemic treatment: results of the CRYSTAL observational study in Central and Eastern European countries. Frontiers in Immunology. 2024;15:1410540. https://doi.org/10.3389/fimmu.2024.1410540

26. Yang J., Hu K., Li X. et al. Psoriatic Foot Involvement is the Most Significant Contributor to the Inconsistency Between PASI and DLQI: A Retrospective Study from China. Clinical, Cosmetic and Investigational Dermatology. 2023;16:443-451. https://doi.org/10.2147/CCID.S396997